Because TARBP2 protein downregulation occurred through the autophagic–lysosomal pathway and induced sorafenib resistance in HCC cells, we further investigated the components downstream of TARBP2 in sorafenib resistance in SR cells. Here, TARBP2 is linked to hepatocellular carcinoma.